[EN] ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS<br/>[FR] COMPOSÉS ACTIVATEURS DU RÉCEPTEUR D'ARYL HYDROCARBONE (AHR) EN TANT QU'AGENTS THÉRAPEUTIQUES CONTRE LE CANCER
申请人:BROAD INST INC
公开号:WO2020102506A1
公开(公告)日:2020-05-22
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided
本公开涉及与诊断和治疗或预防癌症有关的组合物和方法,特别是涉及表达FOXA1和/或FOXA1基因靶点升高的癌症,例如某些乳腺癌、肝癌和/或前列腺癌,包括乳腺癌的分泌性和/或ER阳性形式。已经确定的三种腺苷受体拮抗剂,CGS-15943、MRS-1220和SCH-58261,以及CGS-15943的呋喃环基团衍生物,专门用于以似乎涉及通过这些化合物激活芳香烃受体(AHR)来杀灭癌细胞。因此,本公开提供选择和/或施用CGS-15943、MRS-1220、SCH-58261和/或CGS-15943的呋喃基团衍生物,MRS-1220和/或SCH-58261作为靶向癌细胞和/或患有或有发展癌症风险的受试者的治疗剂的方法。还提供了包括这些化合物的治疗方法和组合物。